BOSTON ( TheStreet) -- Shares of Vivus (VVUS) and Arena Pharmaceuticals (ARNA) rose Wednesday after Aetna (AET) said it would provide medical benefit coverage for the companies' respective prescription weight-loss pills.
The nation's third-largest insurer issued a policy bulletin update on Tuesday in which Vivus' Qsymia and Arena's Belviq were added to a list of "medically necessary weight loss reduction medicines."
Aetna's coverage decision could provide a financial incentive for obese patients to consider weight-loss pills. For this reason, Vivus shares rose 13% to $11.70; Arena shares increased 3% to $9.16 in Wednesday trading
Approximately 30% of patients prescribed Qsymia choose not to pick up their prescription due to the high out-of-pocket cost. This high rate of prescription abandonment has been cited by Vivus executives as one of the significant reasons for the weight-loss pill's disappointing commercial launch.Vivus said approximately 20% of patients were receiving insurance reimbursement coverage for Qsymia with an average co-pay of $60 per month. Aetna's decision to cover Qsymia and Arena's Belviq is a significant addition. Aetna's coverage of Qsymia and Belviq is as a medical benefit and not a pharmacy benefit, and comes with other restrictions. The medicines will be considered medically necessary only for members who fail to lose at least one pound per week after at least six months on a weight-loss regimen that includes diet and exercise. Members also have to have a body mass index greater than 30 or a body mass index greater than 27 plus other risk factors. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV